Key result
Rapid high-dose IV acyclovir yields favorable outcomes in immunosuppressed chickenpox patients while delayed treatment proves fatal.
Why the study?
Does prompt treatment with high dose intravenous acyclovir improve clinical outcomes in immunosuppressed adults with chickenpox?
Case Report (n=2)
No
Does prompt treatment with high dose intravenous acyclovir improve clinical outcomes in immunosuppressed adults with chickenpox?
Adults with immunosuppression who develop chickenpox require prompt systemic treatment with acyclovir to prevent potentially fatal outcomes.
Answers are grounded in this paper and cite their sources.
May support prompt high-dose acyclovir in immunosuppressed adults with chickenpox; leaves open confirmation in prospective trials.
BACKGROUND: We report our experience with two patients with adult onset of chickenpox in the setting of longstanding steroid therapy for nephrotic syndrome. Ours is a 430-bed tertiary care teaching hospital, The Wellesley Hospital, Toronto, Ontario. Both patients presented as self-referrals to the emergency department. METHODS: The clinical suspicion of chickenpox was rapidly confirmed in both cases by a Tzanck smear preparation, by viral cultures of the vesicle, serology, and skin biopsy. In both patients therapy with high dose acyclovir, 10 mg/kg q8h, intravenously, was instituted based on clinical presentation. RESULTS: Delay in clinical recognition and treatment in our first case resulted in death due to multiorgan failure (MOF). Improved awareness and rapid treatment of the second patient had a favorable outcome with no sequelae. CONCLUSIONS: Chickenpox is not only a childhood illness. Although rare in the adult population, it is associated even in the nonimmunocompromised host with increased morbidity and mortality. Steroid therapy predisposes to early dissemination and a potentially fatal outcome. Adults with immunosuppression should receive prompt systemic treatment with acyclovir.
No takes yet. Share an insight, caveat, or question.
MATÉ et al. (1993) conducted a case report in Adult onset chickenpox with nephrotic syndrome on steroid therapy (n=2). Acyclovir was evaluated on Clinical outcome (survival/death). High dose intravenous acyclovir for adult-onset chickenpox in immunosuppressed patients resulted in death when delayed, but a favorable outcome with no sequelae when administered rapidly.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: